Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Orexo plans NDA for sublingual buprenorphine/naloxone product

Aug. 22, 2012

FDA approves new dosages of sublingual film for opioid dependence

Aug. 21, 2012

Pivotal BEMA-buprenorphine/naloxone trial advances

Aug. 21, 2012

Buprenorphine/naltrexone combination evaluated in experimental cocaine dependence

Aug. 20, 2012

Study identifies role of thrombomodulin-aPC pathway in radioprotection

Aug. 7, 2012

Antinicotine gene therapy as a novel approach to nicotine addiction

July 20, 2012

Soligenix receives grant for acute radiation syndrome therapy

July 18, 2012

Topline results expected early from phase IIb study of vigabatrin

July 16, 2012

BioDelivery Sciences reports on BEMA-buprenorphine/naloxone study

July 4, 2012

Orexo completes dose proportionality study of opioid dependence drug

June 19, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...